Scholtz & Company’s Boston Scientific BSX Stock Holding History

Scholtz & Company’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,957	Closed	-$3.01M	–	50
2026 Q1	$3.01M	Buy	+47,957	New	+$3.84M	1.54%	32

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Scholtz & Company's BSX Position: Q2 2026 in Review

Scholtz & Company sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 47,957 shares — an estimated $3.01M sold.

Scholtz & Company first reported a position in BSX in Q1 2026 and held it in 1 quarter. The position peaked at $3.01M in Q1 2026. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Scholtz & Company reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Scholtz & Company sold 47,957 Boston Scientific shares in Q2 2026, an estimated $3.01M.
Scholtz & Company first reported a position in Boston Scientific in Q1 2026 and held it in 1 quarter.
Scholtz & Company's Boston Scientific position peaked at $3.01M in Q1 2026.
1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Scholtz & Company's 13F filing for Q2 2026, filed 11 Aug 2026.